Evidence map›Paper›PMID 36763597›Full record

ArticlePloS one2023

Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.

Dimitrios Makrakis, Konstantinos Rounis, Alexandros-Pantelis Tsigkas, Alexandra Georgiou, Nikolaos Galanakis, George Tsakonas, Simon Ekman, Chara Papadaki, Alexia Monastirioti, Meropi Kontogianni and 3 more

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Dimitrios MakrakisDepartment of Medical Oncology, University General Hospital, Heraklion, Crete, Greece.ORCID 0000-0003-3258-2984
Konstantinos RounisDepartment of Medical Oncology, University General Hospital, Heraklion, Crete, Greece.
Alexandros-Pantelis TsigkasDepartment of Nutrition & Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
Alexandra GeorgiouDepartment of Nutrition & Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
Nikolaos GalanakisDepartment of Medical Imaging, University General Hospital, Heraklion, Crete, Greece.ORCID 0000-0001-9878-6053
George TsakonasComprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Simon EkmanComprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Chara PapadakiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.ORCID 0000-0002-4591-3757
Alexia MonastiriotiLaboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
Meropi KontogianniDepartment of Nutrition & Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
Ioannis GioulbasanisDepartment of Medical Oncology, Animus Kyanus Stavros General Clinic, Larissa, Greece.
Dimitris MavroudisDepartment of Medical Oncology, University General Hospital, Heraklion, Crete, Greece.
Sofia AgelakiDepartment of Medical Oncology, University General Hospital, Heraklion, Crete, Greece.
University of Crete · GRHarokopio University of Athens · GRKarolinska University Hospital · SEJacobi Medical Center · USUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and sarcopenia have been reported to affect outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). We analyzed prospective data from 52 patients with non-oncogene driven metastatic NSCLC treated with ICIs. Body tissue composition was calculated by measuring the fat and muscle densities at the level of 3rd lumbar vertebra in each patient computed tomography scan before ICI initiation using sliceOmatic tomovision. We converted the densities to indices [Intramuscular Fat Index (IMFI), Visceral Fat Index (VFI), Subcutaneous Fat Index (SFI), Lumbar Skeletal Muscle Index (LSMI)] by dividing them by height in meters squared. Patients were dichotomized based on their baseline IMFI, VFI and SFI according to their gender-specific median value. The cut-offs that were set for LMSI values were 55 cm2/m2 for males and 39 cm2/m2 for females. SFI distribution was significantly higher (p = 0.040) in responders compared to non-responders. None of the other variables affected response rates. Low LSMI HR: 2.90 (95% CI: 1.261-6.667, p = 0.012) and low SFI: 2.20 (95% CI: 1.114-4.333, p = 0.023) values predicted for inferior OS. VFI and IMFI values did not affect survival. Subcutaneous adipose and skeletal muscle tissue composition significantly affected immunotherapy outcomes in our cohort.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsFemaleHumansImmune Checkpoint InhibitorsMaleObesityPrognosisProgrammed Cell Death 1 ReceptorProspective StudiesRetrospective StudiesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Identifiers

PMID36763597
PMCPMC9916610
OpenAlexW4319825922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.